Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: A retrospective observational study

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2556-2562

  Fehér, Csaba ^a   Rovira, Montserrat ^a,b   Soriano, Alex ^a,b,c   Esteve, Jordi ^a,b   Martínez, José Antonio ^a,b   Marco, Francesc ^a,d   Carreras, Enric ^a,b   Martínez, Carmen ^a,b   Fernández Avilé, Francesc ^a,b   Suárez Lledó, María ^a,b   Mensa, Josep ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

B lactams; Neutropenic fever; Prolonged antibiotic infusion

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; GLYCOPEPTIDE; MEROPENEM; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; THIENAMYCIN DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; CONVENTIONAL SHORT INFUSION; DRUG EFFECT; DRUG EFFICACY; EXTENDED INFUSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; INFUSION; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MYELOID LEUKEMIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHYSICAL DISEASE BY BODY FUNCTION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ADVERSE EFFECTS; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FEBRILE NEUTROPENIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 84905980394     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku150     Document Type: Article

References (41)

1. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289-97.
2. Turnidge JD. The pharmacodynamics of b-lactams. Clin Infect Dis 1998; 27: 10-22.
3. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.
4. Tam VH, Schilling AN, Neshat S et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 4920-7.
5. Ong CT, Tessier PR, Li C et al. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 2007; 57: 153-61.
6. Mattoes HM, Kuti JL, Drusano GL et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26: 1187-98.
7. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
8. Kuti JL, Dandekar PK, Nightingale CH et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-23.
9. Roberts JA, Kirkpatrick CMJ, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
10. Lee D-G, Choi S-M, Shin W-S et al. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 2006; 28: 333-9.
11. Ohata Y, Tomita Y, Nakayama M et al. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis. J Infect Chemother 2011; 17: 831-41.
12. Ariano RE, Nyhlén A, Donnelly JP et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39: 32-8.
13. Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46: 1171-8.
14. Abbott IJ, Roberts JA. Infusional b-lactam antibiotics in febrile neutropenia: has the time come?. Curr Opin Infect Dis 2012; 25: 619-25.
15. Moriyama B, Henning S, Childs R et al. High-dose continuous infusion b-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010; 44: 929-35.
16. Marshall E, Smith DB, Reilly SMO et al. Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients. Support Care Cancer 2000; 8: 198-202.
17. Dalle J-H, Gnansounou M, Husson M-O et al. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediatr Hematol Oncol 2002; 24: 714-6.
18. Daenen S, Erjavec Z, Uges DR et al. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995; 14: 188-92.
19. Egerer G, Goldschmidt H, Salwender H et al. Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents 2000; 15: 119-23.
20. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
21. Paul M, Yahav D, Fraser A et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57: 176-89.
22. Perrott J, Mabasa VH, Ensom MHH. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann Pharmacother 2010; 44: 557-64.
23. Jaruratanasirikul S, Limapichat T, Jullangkoon M et al. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents 2011; 38: 231-6.
24. Lorente L, Lorenzo L, Marti{dotless}́nMMet al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gramnegative bacilli. Ann Pharmacother 2006; 40: 219-23.
25. Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extendedinfusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
26. Chytra I, Stepan M, Benes J et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012; 16: R113.
27. Shiu J, Wang E, Tejani AM et al. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev 2013; issue 3: CD008481.
28. Korbila IP, Tansarli GS, Karageorgopoulos DE et al. Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert Rev Anti Infect Ther 2013; 11: 585-95.
29. Tamma PD, Putcha N, Suh YD et al. Does prolonged b-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials. BMC Infect Dis 2011; 11: 181.
30. Roberts JA, Webb S, Paterson D et al. A systematic review on clinical benefits of continuous administration of b-lactam antibiotics. Crit Care Med 2009; 37: 2071-8.
31. Kasiakou SK, Sermaides GJ, Michalopoulos A et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5: 581-9.
32. Falagas ME, Tansarli GS, Ikawa K et al. Clinical outcomes with extended or continuous versus short-termintravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56: 272-82.
33. Marena C, Zecca M, Carenini ML et al. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect Control Hosp Epidemiol 2001; 22: 510-7.
34. Magauran CE, Salgado CD. Challenges and advances in infection control of hematopoietic stem cell transplant recipients. Infect Disord Drug Targets 2011; 11: 18-26.
35. Mendes ET, Dulley F, Basso M et al. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. Int J Infect Dis 2012; 16: e424-8.
36. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41 Suppl D: 13-24.
37. Hakim H, Flynn PM, Knapp KM et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009; 31: 623-9.
38. Elting LS, Rubenstein EB, Rolston K et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 2000; 18: 3699-706.
39. Mayordomo JI, López A, Vin{ogonek} olas N et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009; 25: 2533-42.
40. Nicolau DP. Current challenges in the management of the infected patient. Curr Opin Infect Dis 2011; 24 Suppl 1: S1-10.
41. MacGowan A. Revisiting b-lactams-PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol 2011; 11: 470-6.